Lipid Profiles in Systemic Juvenile Idiopathic Arthritis Patients With and Without Lung Disease

Timothy Klouda(Boston Children's Hospital), Martha P. Fishman(Boston Children's Hospital), Mary Beth F. Son(Boston Children's Hospital), Katie A. Krone(Boston Children's Hospital), Olha Halyabar(Boston Children's Hospital), Alicia Casey(Boston Children's Hospital)
Unknown
May 1, 2021
10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3262
Cited by 0

Related Papers

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
|New England Journal of Medicine|2020|2.7k
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
|JAMA|2021|852
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
|Arthritis & Rheumatology|2020|537
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2
|Arthritis & Rheumatology|2020|415